SCHEMBL14897445

SCHEMBL14897445

CN(C)[C@H]1CCN(c2ccc3ncc(C(=O)Nc4cccc(N5CCOCC5)n4)n3n2)C1

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ IRAK4 Q9NWZ3 3/20 0.45
▸ AAK1 Q2M2I8 4/20 0.41
▸ MCHR1 Q99705 2/20 0.41
▸ KIF18A Q8NI77 5/20 0.40
▸ CLK2 P49760 1/20 0.40
▸ GSK3A P49840 1/20 0.40
▸ GSK3B P49841 1/20 0.40
▸ CSNK2A1 P68400 1/20 0.40
▸ STK3 Q13188 1/20 0.40
▸ HIPK4 Q8NE63 1/20 0.40
▸ CLK4 Q9HAZ1 1/20 0.40
▸ JAK1 P23458 1/20 0.39
▸ CREBBP Q92793 1/20 0.39
▸ WDR5 P61964 2/20 0.38
▸ ACACB O00763 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14897149 1.00 IRAK4 (0.45) IRAK4AAK1MCHR1KIF18ACLK2
SCHEMBL14897641 0.88 IRAK4 (0.49) IRAK4KIF18ACLK2GSK3AGSK3B
SCHEMBL14882293 0.88 IRAK4 (0.49) IRAK4KIF18ACLK2GSK3AGSK3B
SCHEMBL14882295 0.88 IRAK4 (0.49) IRAK4KIF18ACLK2GSK3AGSK3B
SCHEMBL14897378 0.84 AAK1 (0.47) IRAK4AAK1MCHR1
SCHEMBL16193126 0.83 IRAK4 (0.48) IRAK4KIF18ACLK2GSK3AGSK3B
SCHEMBL18654751 0.83 IRAK4 (0.41) IRAK4AAK1MCHR1ACACB
SCHEMBL18655207 0.83 IRAK4 (0.41) IRAK4AAK1MCHR1ACACB
SCHEMBL14896770 0.82 AAK1 (0.45) IRAK4AAK1MCHR1
SCHEMBL14897035 0.82 AAK1 (0.49) IRAK4AAK1MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180186801-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2018-07-05 — — US disclosed
US-20180186801-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2018-07-05 — — US disclosed
US-9957271-B2 Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2018-05-01 — — US disclosed
US-9957271-B2 Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2018-05-01 — — US disclosed
EP-2768509-B1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2017-03-22 — — EP disclosed
US-20140349993-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2014-11-27 — — US disclosed
US-20140349993-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2014-11-27 — — US disclosed
WO-2013059587-A9 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2014-10-23 — — WO disclosed
WO-2013059587-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2013-04-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140349993-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 IRAK4 3168/4885AAK1 2011/4885MCHR1 3729/4885
US-20180186801-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 IRAK4 3168/4885AAK1 2011/4885MCHR1 3729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback